OM Pharma and Medinfar enter into exclusive agreement to promote Broncho-Vaxom® in Portugal

OM Pharma enters into a promotion agreement granting Medinfar the exclusive right to promote the immunological therapy Broncho-Vaxom® for the prevention of respiratory tract infections in Portugal The promotion agreement grants Medinfar, a Portuguese pharmaceutical group, the exclusive right to promote OM Pharma’s Broncho-Vaxom® (Bacterial Lysates - OM-85) in Portugal. Broncho-Vaxom® is a therapeutic agent that prevents recurrent respiratory tract infections in adult and paediatric patients by boosting the host immunity. This agreement marks yet another synergistic collaboration with a leading local player, demonstrating OM Pharma’s ability to establish strategic partnerships. The longstanding commercial experience of Medinfar will consolidate the position of Broncho-Vaxom® in Portugal and strengthen OM Pharma’s impact in the field of respiratory and immunological diseases to support more patients who are suffering from recurrent respiratory tract infections.

The release as fetched from its publisher. ompharma.com ↗